Screener
AbbVie ABBV Q3 2026 earnings
Reported October 30, 2026 · Before market open
Revenue$17.4BBeat by $88.3M
Adjusted EPS$3.82Beat by $0.09
Revenue estimate$17.3B
EPS estimate$3.73
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”
Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.
Next report
Oct 30, 2026 (Today)Revenue estimate$17.3B
EPS estimate$3.73
Financials
Q3 2026Income statement
Valuation & ratios
Segments
By product
Versus estimates
Revenue
FAQ
- When did AbbVie report Q3 2026 earnings?
- AbbVie (ABBV) reported Q3 2026 earnings on October 30, 2026 before market open.
- What were AbbVie's Q3 2026 revenue and EPS?
- AbbVie reported revenue of $17.4B and adjusted eps of $3.82 for Q3 2026.
- Did AbbVie beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $17.3B by $88.3M. EPS beat the consensus estimate of $3.73 by $0.09.
- How did AbbVie's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 10.3% from $15.8B a year earlier.
- Where can I find AbbVie's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001551152-26-000033) directly on SEC EDGAR. The filing index links above go to sec.gov.
